Closing Cancer Gaps with Genomic Data for Better Outcomes

Bharat Cancer Genome Atlas (BCGA) is a public database launched by the Indian Institute of Technology (Madras) to systematically map cancer genomes in Indian patients. Its primary objective is to address the underrepresentation of Indian populations in global cancer-genome studies, ensuring that clinicians and researchers have access to India-specific genomic insights.

The BCGA aims to achieve several key outcomes:

• Facilitate early diagnosis of cancers by identifying India-specific genetic variants.
• Enable monitoring of disease progression and personalized treatment decisions.
• Support drug development targeted at genetic mutations prevalent in Indian populations.

Genomic research and testing are crucial because they provide insights into the genetic basis of cancer, which can guide personalized treatment strategies and improve patient outcomes. India has a rising cancer burden, with one in nine Indians projected to develop the disease and 2.5 million people currently living with it. Despite this, Indian patients have historically been underrepresented in global genomic studies, limiting the relevance of international findings for local treatment.

Genomic testing enables doctors to understand disease progression, identify mutations that may respond to specific therapies, and select targeted drugs rather than relying on generalized chemotherapy. For example, whole exome sequencing can reveal mutations that may make a patient eligible for a precision therapy, improving survival rates while reducing unnecessary side effects.

Furthermore, genomic research informs public health strategies by identifying population-specific risk patterns. It also accelerates drug discovery and the development of therapies that are both effective and affordable for Indian patients, addressing gaps in treatment efficacy due to genetic diversity.

Initiatives like BCGA and Bharat Cancer Genome Grid (BCG2) improve access by providing a structured genomic framework that clinicians can use to make informed treatment decisions. The BCG2 platform allows doctors to leverage the data collected in BCGA to recommend precision therapies and monitor patient progress.

By consolidating genomic data across multiple cancers, these initiatives bridge the knowledge gap between genetic research and clinical application. They also standardize treatment protocols and facilitate collaboration among hospitals, research institutions, and pharmaceutical companies, enabling faster adoption of advanced therapies.

Moreover, as domestic genomic testing becomes more affordable and widely available, these platforms can guide clinical decision-making even in smaller hospitals or regions outside major urban centers. This ensures that patients in tier-2 and tier-3 cities benefit from the same precision medicine insights as those in metropolitan hospitals, reducing disparities in care.

Unequal access to advanced cancer care in India arises from multiple structural and socioeconomic factors:

• Shortage of trained professionals: There is a limited number of genetic counsellors, molecular pathologists, and bioinformaticians capable of interpreting complex genomic tests.
• High costs: Advanced diagnostics and therapies remain expensive, with treatment costs ranging from ₹2 lakh to ₹10 lakh per month, often beyond the reach of lower-income patients.
• Concentration of facilities: State-of-the-art diagnostic and treatment centers are predominantly in major cities, requiring rural and small-town patients to travel long distances, incurring out-of-pocket expenses.
• Limited insurance coverage: Many genomic tests are not covered by insurance, further restricting access for economically disadvantaged populations.

Falling genomic test prices, which have decreased by 30-40% for routine tests in recent years, are a positive step towards democratizing access to precision oncology in India. Lower costs make genomic testing more attainable for hospitals and patients, encouraging early detection and personalized treatment strategies.

However, price reduction alone does not guarantee equitable access. There remain critical bottlenecks including a shortage of trained professionals to interpret results, limited insurance coverage, and concentration of advanced diagnostic facilities in metropolitan areas. For example, a patient in a rural area may have access to a cheaper genomic test but lack the guidance to translate results into actionable treatment decisions.

Thus, while falling costs are necessary, they are insufficient on their own. A holistic approach is required, combining affordability with workforce development, insurance coverage, and regional distribution of diagnostic services. Only then can precision oncology achieve its intended impact across diverse socioeconomic strata.

The Union Budget 2026-27 highlights several government interventions aimed at improving affordability and access to cancer care in India. These include:

• Increasing health sector allocation by nearly 10%, enabling greater funding for public hospitals and preventive programs.
• Exempting Customs duties on 17 cancer drugs, which reduces the cost of treatment for patients requiring expensive medications.
• Promoting domestic biopharmaceutical manufacturing, which lowers dependency on imports and encourages the development of affordable therapies.

India can leverage BCGA data to implement precision medicine strategies that target the genetic variants most prevalent in Indian populations. By identifying high-risk mutations, clinicians can prioritize early screening, targeted therapies, and proactive monitoring, which reduces both morbidity and mortality.

For example, if BCGA data shows a high prevalence of a specific mutation in breast cancer among Indian women, screening protocols can be tailored, and targeted therapies can be prioritized for these patients. This enables interventions at earlier stages when treatments are more effective and less costly.

Additionally, integrating BCGA with platforms like BCG2 allows doctors across India to access real-time genomic insights, guiding treatment decisions even in non-metropolitan regions. When combined with broader insurance coverage and expansion of diagnostic facilities, this approach can democratize precision oncology, transforming cancer care from a reactive, high-cost model to a proactive, India-specific, and outcome-driven system.